Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 to 24 mg) were administered to 13 such subjects (11 had tophaceous gout), whose plasma uric acid concentration (pUAc) was 11.3 ± 2.1 mg/dl (mean ± SD). By day seven after injection of PEG-uricase, pUAc had declined by an average of 7.9 mg/dl and had normalized in 11 subjects, whose mean pUAc decreased to 2.8 ± 2.2 mg/dl. At doses of 8, 12, and 24 mg, the mean pUAc at 21 days after injection remained no more than 6 mg/dl. In eight subjects, plasma uricase activity was still measurable at 21 days after injection (half-life 10.5 to 19.9 days). In the other five subjects, plasma uricase activity could not be detected beyond ten days after injection; this was associated with the appearance of relatively low-titer IgM and IgG antibodies against PEG-uricase. Unexpectedly, these antibodies were directed against PEG itself rather than the uricase protein. Three PEG antibody-positive subjects had injection-site reactions at 8 to 9 days after injection. Gout flares in six subjects were the only other significant adverse reactions, and PEG-uricase was otherwise well tolerated. A prolonged circulating life and the ability to normalize plasma uric acid in markedly hyperuricemic subjects suggest that PEG-uricase could be effective in depleting expanded tissue stores of uric acid in subjects with chronic or tophaceous gout. The development of anti-PEG antibodies, which may limit efficacy in some patients, is contrary to the general assumption that PEG is non-immunogenic. PEG immunogenicity deserves further investigation, because it has potential implications for other PEGylated therapeutic agents in clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 Competition ELISA to determine the specificity of IgG antibody against PEG-uricase. Increasing amounts of the indicated materials were added to aliquots of plasma obtained from subject 013 on day 14 after subcutaneous injection of 12 mg of PEG-modified recombinant mammalian urate oxidase (PEG-uricase). After incubation overnight, these mixtures were tested at a 1:60 dilution in the ELISA for IgG antibody against PEG-uricase. (a) 'Uricase' is the unmodified recombinant protein used in PEG-uricase, and 'PEG 10000' is 10 K monomethoxyPEG (mPEG) conjugated with glycine instead of uricase protein. 'PEG-PNP' is bacterial purine nucleoside phosphorylase conjugated with mPEG of molecular mass 5 kDa, prepared as described [18]. (b) 'PEG 350' and 'PEG 2000' are unconjugated, nonactivated mPEGs of molecular masses 350 and 2,000 Da. 'PEG 5000' and 'PEG 10000' are p-nitrophenyl carbonate-activated mPEGs of the indicated molecular masses conjugated with glycine.](https://figures.cochat.ai/paper-figures/f8a8191cc8f9401e9fb6bf56f5998352/control-of-hyperuricemia-in-subjects-with-refractory-gout-and-induction-of-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase I study of refractory gout, patients were treated with a PEG-uricase therapy. About one third of the treatment group, who had previously been treated with pegylated therapies at some point, had previously developed anti-PEG antibodies in the body. This resulted in lower AUC’s and poor efficacy of the PEG-uricase treatment [80].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“PEGylation has since been used to enhance the therapeutic utility of several other proteins, as well as liposomes, low-molecular-mass drugs, oligonucleotides, lipids, and polysaccharides [11].”
BackgroundMolecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Kelley's Textbook of Rheumatology
(2013) · Elsevier eBooks · doi:10.1016/c2009-1-62542-9 · Cited by 1,101
Poly(ethylene glycol): Chemistry and Biological Applications
(1997) · ACS Symposium Series · doi:10.1021/bk-1997-0680 · Cited by 646
Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
A specific enzyme defect in gout associated with overproduction of uric acid.
Kelley, W. N., Rosenbloom, F. M., Henderson, J. F., & Seegmiller, J. E. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1735 · Cited by 475
Research works printed but not linked: 1
- Ganson N, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS: Antibodies to polyethylene glycol (PEG) during phase I investigation of PEG-urate oxidase (PEG-uricase; Puricase®) for refractory gout [abstract]. Arthritis Rheum. 2004, 50: s338-
Cited by
Items 201–300 of 346
Role of stealth lipids in nanomedicine-based drug carriers
Rastogi, M., Saha, R. N., Alexander, A., Singhvi, G., Puri, A., & Dubey, S. K. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2020.105036 · Cited by 27
Zeunik, R., Ryuzoji, A. F., Peariso, A., Wang, X., Lannan, M. B., Spindler, L. J., Knierman, M. D., Copeland, V., Patel, C. N., & Wen, Y. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.05.005 · Cited by 26
Thermoresponsive coacervate formation of random poly(phosphonate) terpolymers
Wolf, T., Rheinberger, T., & Wurm, F. R. (2017) · European Polymer Journal · doi:10.1016/j.eurpolymj.2017.05.048 · Cited by 24
Zhao, R., Zhang, Y., Ruan, B., Zhang, H., Lv, N., Li, J., Yang, Y. R., Luo, X., & Lu, H. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202425559 · Cited by 21
PEGylation and anti-PEG antibodies
Lila, A. S. A., Shimizu, T., & Ishida, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-08-101750-0.00003-9 · Cited by 27
Li, Z., Shen, L., Ma, A. L., Talkington, A., Li, Z., Nyborg, A. C., Bowers, M. S., LaMoreaux, B. D., Livingston, E. W., Frank, J. E., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.08.052 · Cited by 20
Design Principles for Immunomodulatory Biomaterials
Oluwole, S. A., Weldu, W. D., Jayaraman, K., Barnard, K. A., & Agatemor, C. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c00537 · Cited by 21
Yainoy, S., Phuadraksa, T., Wichit, S., Sompoppokakul, M., Songtawee, N., Prachayasittikul, V., & Isarankura‐Na‐Ayudhya, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061269 · Cited by 21
Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo
An, Y., Li, X., Yao, F., Duan, J., & Yang, X. (2022) · Molecules · doi:10.3390/molecules27051482 · Cited by 19
The Emerging Role of Biotechnological Drugs in the Treatment of Gout
Cavagna, L., & Taylor, W. J. (2014) · BioMed Research International · doi:10.1155/2014/264859 · Cited by 19
Khuphe, M., Mahon, C. S., & Thornton, P. D. (2016) · Biomaterials Science · doi:10.1039/c6bm00535g · Cited by 21
Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines
Shiraishi, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2538423 · Cited by 24
Choi, J., Zhu, Y., Li, H., Peyda, P., Nguyen, T. T., Shen, M.-Y., Yang, Y., Zhu, J., Liu, M., Lee, M. M., et al. (2016) · ACS Nano · doi:10.1021/acsnano.6b06200 · Cited by 18
Turecek, P. L., & Siekmann, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-444-64081-9.00004-8 · Cited by 26
Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities
Mihindukulasooriya, S. P., Wang, Z., Li, S., Saini, A., Wilson, K., Plebanski, M., Kent, S. J., & Ju, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115925 · Cited by 20
Siebel, C., Lanvers‐Kaminsky, C., Alten, J., Smíšek, P., Nath, C. E., Rizzari, C., Boos, J., & Würthwein, G. (2021) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00741-w · Cited by 17
Rubinstein, M. P., Salem, M. L., Doedens, A. L., Moore, C. J., Chiuzan, C. C., Rivell, G. L., Cole, D. J., & Goldrath, A. W. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-75 · Cited by 17
Feng, J., Liu, H., Yang, X., Gao, A., Liao, J., Feng, L., Pu, J., Xie, Y., Long, G., Li, Y., et al. (2013) · Chemistry Central Journal · doi:10.1186/1752-153x-7-69 · Cited by 19
Bessen, S. Y., Bessen, M. Y., & Yung, C. M. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.11.006 · Cited by 17
A rheumatoid factor paradox: inhibition of rituximab effector function
Jones, J. D. G., Shyu, I., Newkirk, M. M., & Rigby, W. F. C. (2013) · Arthritis Research & Therapy · doi:10.1186/ar4152 · Cited by 17
Safety of recombinant coagulation factors in treating hemophilia
Morfini, M., & Rapisarda, C. A. P. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1574743 · Cited by 17
Sayed, M. M. E., Shimizu, T., Lila, A. S. A., Elsadek, N. E., Emam, S. E., Alaaeldin, E., Kamal, A., Sarhan, H. A., Ando, H., Ishima, Y., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121539 · Cited by 16
Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines
Cen, J., Hou, M., & Liu, S. (2023) · Giant · doi:10.1016/j.giant.2023.100169 · Cited by 18
Influence of PEGylation on the Strength of Protein Surface Salt Bridges
Xiao, Q., Draper, S. R. E., Smith, M. S., Brown, N. P., Pugmire, N. A. B., Ashton, D. S., Carter, A. J., Lawrence, E. E. K., & Price, J. L. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00432 · Cited by 16
Lioté, F., & Bardin, T. (2006) · Revue du Rhumatisme · doi:10.1016/j.rhum.2006.12.005 · Cited by 15
Expression and function of CXCL16 in a novel model of gout
Ruth, J. H., Arendt, M. D., Amin, M. A., Ahmed, S., Marotte, H., Rabquer, B. J., Lesch, C. A., Lee, S., & Koch, A. E. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27518 · Cited by 15
Treatment of Crystal Arthropathy—History and Advances
Nuki, G. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.03.003 · Cited by 15
Freyne, B. (2018) · Transplantation Proceedings · doi:10.1016/j.transproceed.2018.03.010 · Cited by 15
Urate-Lowering Therapy for the Management of Gout: A Summary of 2 Cochrane Reviews
Kydd, A. S., Seth, R., Buchbinder, R., Falzon, L., Edwards, C. J., van der Heijde, D. M. F. M., & Bombardier, C. (2014) · Journal of Rheumatology Supplement · doi:10.3899/jrheum.140460 · Cited by 15
Current and Future Therapeutic Options for the Management of Gout
Whelton, A. (2010) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181df8ad2 · Cited by 14
Reassessing serum urate targets in the management of refractory gout: can you go too low?
Hershfield, M. S. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283257b83 · Cited by 14
Self-citationRevisão crítica do tratamento medicamentoso da gota no Brasil
Azevedo, V. F., Lopes, M. P., Catolino, N. M., Paiva, E. D. S., Araújo, V. A., & Pinheiro, G. D. R. C. (2017) · Revista Brasileira de Reumatologia · doi:10.1016/j.rbr.2016.06.009 · Cited by 13
Vainshtein, I., Sun, B., Roskos, L. K., & Liang, M. (2019) · Journal of Immunological Methods · doi:10.1016/j.jim.2019.112688 · Cited by 13
Krishna, M., Palme, H., Duo, J., Lin, Z., Corbett, M. J., Dodge, R. W., Piccoli, S. P., Myler, H. A., Pillutla, R. C., & Desilva, B. S. (2015) · Bioanalysis · doi:10.4155/bio.15.112 · Cited by 13
Punnappuzha, A., JagadeeshBabu, P. E., Nishith, R. S., Hadigal, S., & Pai, P. G. (2014) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-014-9411-2 · Cited by 13
Generation and Characterization of a Monoclonal IgG Antibody to Polyethylene Glycol
Wunderlich, D. A., MacDougall, M. L., Mierz, D. V., Toth, J. G., Buckholz, T. M., Lumb, K. J., & Vasavada, H. A. (2007) · Hybridoma · doi:10.1089/hyb.2007.006 · Cited by 13
Induction of Anti-PEG Immune Responses by PEGylation of Proteins
Shimizu, T., Ishima, Y., & Ishida, T. (2020) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.19-00187-5 · Cited by 14
Bivi, N., Swearingen, C., Shockley, T. E., Sloan, J. H., Pottanat, T. G., Carter, Q. L., Hodsdon, M. E., Siegel, R. W., & Konrad, R. J. (2020) · Journal of Immunological Methods · doi:10.1016/j.jim.2020.112856 · Cited by 13
Trützschler, A., Buś, T., Sahn, M., Traeger, A., Weber, C., & Schubert, U. S. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00362 · Cited by 13
Poly(2-ethyl-2-oxazoline)-Conjugated Hemoglobins as a Red Blood Cell Substitute
Okamoto, W., Hiwatashi, Y., Kobayashi, T., Morita, Y., Onozawa, H., Iwazaki, M., Kohno, M., Tomiyasu, H., Tochinai, R., Georgieva, R. T., et al. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00392 · Cited by 12
Surface energy of phospholipid bilayers and the correlation to their hydration
Klapper, Y., Vrânceanu, M., Ishitsuka, Y., Evans, D., Scheider, D., Nienhaus, G. U., & Leneweit, G. (2012) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2012.09.027 · Cited by 12
Nanomedicine development for autoimmune diseases
Fang, Y., Thiele, G. M., & Wang, D. (2011) · Drug Development Research · doi:10.1002/ddr.20479 · Cited by 12
Poly(L-glutamic acid)-co-poly(ethylene glycol) block copolymers for protein conjugation
Maso, K., Grigoletto, A., Raccagni, L., Bellini, M., Marigo, I., Ingangi, V., Suzuki, A., Hirai, M., Kamiya, M., Yoshioka, H., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.05.015 · Cited by 12
Clinical Features and Treatment of Gout
Burns, C. M., & Wortmann, R. L. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00095-5 · Cited by 12
Beitzinger, B., Draphoen, B., Hald, J., Krämer, M., Rudolf, T., Schmitt, F., Schwarz, P., & Lindén, M. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2522245 · Cited by 12
Okada, N., Shimizu, T., Ando, H., Nakamura, S., Goda, M., Abe, M., Kitahara, T., Ishida, T., & Ishizawa, K. (2023) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1225 · Cited by 13
Is Gout Associated with Pyoderma Gangrenosum? A Population-Based Case-Control Study
Kridin, K., Ludwig, R. J., Bitan, D. T., Kridin, M., Damiani, G. B., & Cohen, A. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061626 · Cited by 11
Aghajani-Lazarjani, H., Vasheghani‐Farahani, E., Barani, L., Hashemi‐Najafabadi, S., Shojaosadati, S. A., Zahediasl, S., Tairahi, T., & Atyabi, F. (2010) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199.2010.488634 · Cited by 11
Ali, S., & Lally, E. V. (2009) · PubMed · Cited by 11
Impact of pegloticase on patient outcomes in refractory gout: current perspectives
Cunha, R. S., Aguiar, R., & Farinha, F. (2018) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s176951 · Cited by 13
Critical appraisal of the role of pegloticase in the management of gout
Ea, H., & Richette, P. (2012) · PubMed Central · doi:10.2147/oarrr.s1743 · Cited by 12
Humphries, J., Fletcher, N. L., Sonderegger, S., Bell, C. A., Kempe, K., & Thurecht, K. J. (2024) · ACS Nano · doi:10.1021/acsnano.4c07317 · Cited by 17
Lim, M. S. H., Ohtsuki, T., Takenaka, F., Kobayashi, K., Akehi, M., Uji, H., Kobuchi, H., Sasaki, T., Ozeki, E., & Matsuura, E. (2021) · Life · doi:10.3390/life11020158 · Cited by 12
Critical revision of the medical treatment of gout in Brazil
Azevedo, V. F., Lopes, M. P., Catolino, N. M., Paiva, E. D. S., Araújo, V. A., & Pinheiro, G. D. R. C. (2017) · Revista Brasileira de Reumatologia (English Edition) · doi:10.1016/j.rbre.2017.03.002 · Cited by 10
Wang, Y.-S., Chen, Y., Dong, C., Wang, Z., Cai, J., Zhao, X., Mo, H., & Zang, S. (2024) · Inorganic Chemistry Frontiers · doi:10.1039/d4qi00573b · Cited by 10
Tuřánek, J., Kosztyu, P., Knötigová, P. T., Bartheldyová, E., Hubatka, F., Odehnalová, N., Mikulík, R., Vaškovicová, N., Čelechovská, H., Kratochvílová, I., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124465 · Cited by 9
McDonnell, T. C. R., Pericleous, C., Laurine, E., Tommasi, R., Garza-García, A., Giles, I., Ioannou, Y., & Rahman, A. (2015) · BMC Biotechnology · doi:10.1186/s12896-015-0222-0 · Cited by 9
Tully, M., Wedepohl, S., Kutifa, D., Weise, C., Licha, K., Schirner, M., & Haag, R. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.04.019 · Cited by 10
Poly(2‐ethyl‐2‐oxazoline) Featuring a Central Amino Moiety
Dirauf, M., Fritz, N., Gottschaldt, M., Weber, C., & Schubert, U. S. (2021) · Macromolecular Rapid Communications · doi:10.1002/marc.202100132 · Cited by 10
Nanda, P., JagadeeshBabu, P. E., & Raju, J. R. (2016) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-016-9251-z · Cited by 9
A patient with arthritis, severe back pain, impaired wound healing, and perforated sigmoid colon
Härle, P., Schlottmann, K., Ehrenstein, B. P., Fleck, M., Glück, T., Herold, T., Schubert, T. E. O., Straub, R. H., & Schölmerich, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68894-6 · Cited by 9
Making way for PEG alternatives
Gao, W., & Zhang, L. (2025) · Nature Materials · doi:10.1038/s41563-025-02381-w · Cited by 9
Valsecchi, C., Gualtierotti, R., Arcudi, S., Ciavarella, A., Schiavone, L., Novembrino, C., Siboni, S. M., Mannucci, P. M., & Peyvandi, F. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008989 · Cited by 9
Zhang, C., Yang, X., Gao, A., Hu, X., Pu, J., Liu, H., Feng, J., Liao, J., Li, Y., & Liao, F. (2014) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1215 · Cited by 8
Li, Z., Gao, X., Yan, X., Deng, Y., & Ma, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01111-4 · Cited by 8
Pande, I. (2006) · Indian Journal of Rheumatology · doi:10.1016/s0973-3698(10)60005-2 · Cited by 8
Nuki, G. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-2864-4.10014-4 · Cited by 8
Edwards, N. L. (2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3_12 · Cited by 7
Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogs
Okamoto, W., Usui, T., Hasegawa, M., Kobayashi, T., Fujisawa, J., Taguchi, K., Matsumoto, K., Kohno, M., Iwazaki, M., Shimano, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-35999-4 · Cited by 7
Jones, C. F., Castner, D. G., & Grainger, D. W. (2012) · Frontiers in nanobiomedical research · doi:10.1142/9789813140431_0006 · Cited by 9
Biological Applications of Hyaluronic Acid Functionalized Nanomaterials
El‐Dakdouki, M. H., & Huang, X. (2011) · ACS symposium series · doi:10.1021/bk-2011-1091.ch011 · Cited by 9
Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout
Hershfield, M. S., Sundy, J. S., Ganson, N. J., & Kelly, S. J. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_13 · Cited by 7
Self-citationNanda, P., & JagadeeshBabu, P. E. (2016) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-016-9518-8 · Cited by 6
Failure of rasburicase therapy in recurrent acute gout with tophi
Hill, C. L., LU, T. Y., Cervelli, M. J., & Mathew, T. H. (2008) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2008.00380.x · Cited by 6
Presenting an Immunogenicity Risk Assessment to Regulatory Agencies
Chamberlain, P. (2008) · Springer eBooks · doi:10.1007/978-0-387-75841-1_13 · Cited by 6
Pérez-Ruiz, F. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.11.011 · Cited by 6
Zhao, R., Zhang, Y., Ruan, B., Zhang, H., Lv, N., Li, J., Yang, Y. R., Luo, X., & Lu, H. (2025) · Angewandte Chemie · doi:10.1002/ange.202425559 · Cited by 5
Gao, X., Yan, X., Wang, R., Li, C., Qiu, Q., Liu, M., Tang, X., Yan, N. J., Li, J., Song, Y., et al. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.01.008 · Cited by 6
Li, H., Huo, J., Sun, D., Jiang, L., Hu, C., Bai, Y., Ma, X., Zhang, H., Shi, X., Zhao, Z., et al. (2020) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-020-00612-w · Cited by 5
Clinical features of gout in a cohort of Italian patients
Zampogna, G., Andracco, R., Parodi, M., & Cimmino, M. A. (2011) · Reumatismo · doi:10.4081/reumatismo.2009.41 · Cited by 5
Chen, C., Li, J., Chen, Y., Gao, Q.-L., Li, N., & Le, S. (2024) · British Journal of Haematology · doi:10.1111/bjh.19605 · Cited by 4
Microbial Uricase and its Unique Potential Applications
Elbanna, K., Alshareef, A., Neyaz, L. A., El-Readi, M. Z., & Abulreesh, H. H. (2024) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.2478/am-2024-0007 · Cited by 5
Strategies to Enhance Protein Delivery
Zhu, Y., Zhuang, W., & Cheng, H. (2025) · Langmuir · doi:10.1021/acs.langmuir.4c04636 · Cited by 4
Pustake, S. O., Bhagwat, P. K., Pillai, S., & Dandge, P. B. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107270 · Cited by 4
Chilewski, S. D., Shields, J., Mora, J. R., & Myler, H. A. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0228-3 · Cited by 4
El‐Naggar, N. E., El-Ewasy, S. M., & El-Shweihy, N. M. (2024) · Microbial Cell Factories · doi:10.1186/s12934-024-02561-4 · Cited by 4
Advances in the use of nanotechnology for treating gout
Wang, Y., Wang, Z., Jiang, H.-J., Ni, L.-H., Ju, H., Wu, Y., & Li, H. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2457315 · Cited by 4
Perspectives des uricases dans la goutte
Garay, R. P., El-Gewely, R., Labaune, J.-P., & Richette, P. (2011) · Revue du Rhumatisme · doi:10.1016/j.rhum.2011.09.007 · Cited by 4
Polymeric Drug Conjugates by Controlled Radical Polymerization
Kim, S.-H., Nguyen, T. H. T., & Maynard, H. D. (2011) · Elsevier eBooks · doi:10.1016/b978-0-08-055294-1.00266-x · Cited by 4
Sivasubramanian, M., Kang, A. R., Han, H. S., Heo, R., Lee, J.-Y., Kim, K. J., Jeon, S. M., Chae, S. Y., Jo, D., Kim, J.-H., et al. (2012) · Macromolecular Research · doi:10.1007/s13233-012-0158-3 · Cited by 4
Drug delivery technologies for autoimmune disease
Phillips, B. E., & Giannoukakis, N. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.527329 · Cited by 6
Zhang, C., Fan, K. C., Luo, H., Cheng, Y., Lu, Y., Zheng, J., Chen, Z., Xue, J., Zhao, Q., Zhang, M., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116892 · Cited by 4
Updates in uricase therapy for gout
Schlesinger, N., & Kaufmann, D. (2025) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001122 · Cited by 3
Hammer, M., Geisweid, L., Junker, N., Wohlfart, S., Skrzypczyk, L., Ackermann, B. C., Herth, J., Studier‐Fischer, A., Mier, W., Auffarth, G. U., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.2.37 · Cited by 3
Molecular engineering approaches to half-life extension of therapeutic biomolecules
WANG, Y., Chang, J., & Liu, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1778569 · Cited by 4
Wang, X., Lu, H., Rong, J., Sun, Z., Zheng, Y., Fan, B., & Jia, Z. (2024) · Open Life Sciences · doi:10.1515/biol-2022-0799 · Cited by 3
Engineered human FcγRIIa fusion: A novel strategy to extend serum half‐life of therapeutic proteins
Jo, M., Ko, S., Hwang, B., Min, S., Ha, J. Y., Lee, J. C., Jang, S., & Jung, S. T. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27374 · Cited by 3
Transcoronary septal ablation in hypertrophic obstructive cardiomyopathy by embolizing microspheres†
Dickmann, B., Baars, T., Heusch, G., & Erbel, R. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht227 · Cited by 3
Exosomes: Cellular capsules for drug delivery in Parkinson’s disease
Samal, J., Demir, S., & Pandit, A. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-50922-0.00006-7 · Cited by 5
Hu, Y., Lu, S., Lin, X., Qin, L., Xu, Z., & Wang, T. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148041 · Cited by 2
Metadata
- Authors
- Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Hershfield, Michael S
- Venue
- Arthritis Research & Therapy
- Published
- 2005-12-02
- Volume
- 8
- Issue
- 1
- Pages
- R12-R12
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC1526556
- OpenAlex
- W1918944513
- Cited by
- 350
- References
- 40
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 14 · 2023: 13 · 2022: 13 · 2021: 16 · 2020: 27 · 2019: 24 · 2018: 18 · 2017: 11 · 2016: 20 · 2015: 11 · 2014: 22 · 2013: 17 · 2012: 28
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Savient Pharmaceuticals
- National Institutes of Health (MO1-RR-30, RR-30)
- National Center for Research Resources (M01 RR 30, MO 1 RR-30)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- refractory gout, hyperuricemia, tophaceous gout, anti-PEG antibodies, subcutaneous injection, gout flares, injection site reactions
- MeSH terms
- Adult, Aged, Carbon Radioisotopes, Female, Gout, Humans, Immunoglobulin G, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Urate Oxidase, Urea, Uric Acid, Hyperuricemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.